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Epidermal growth factor potentiates renal cell death in hy-
dronephrotic neonatal mice, but cell survival in rats.
Background. Epidermal growth factor (EGF) markedly
attenuates tubular apoptosis induced by unilateral ureteral
obstruction (UUO) in the neonatal rat, and reduces apopto-
sis induced by mechanical stretch of cultured rat tubular cells.
Methods. To investigate the role of EGF in modulating apop-
tosis resulting from UUO, neonatal wild type and mutant mice
lacking EGF (knockout), or with diminished EGF receptor ac-
tivity (waved-2 mutant) were compared to control mice for
tubular apoptosis and atrophy. Rat and mouse kidneys were
compared for localization of the EGF receptor. Apoptosis was
also measured in cultured mouse tubular cells subjected to
stretch and exposed to EGF.
Results. UUO reduced endogenous renal EGF expression
in wild-type mice. Unlike the rat, exogenous EGF did not de-
crease tubular apoptosis or atrophy in the obstructed kidney,
and significantly increased stretch-induced apoptosis of cul-
tured mouse tubular cells. Tubular apoptosis was 50% lower
in the obstructed kidney of EGF knockout and waved-2 mice
relative to wild type and heterozygous animals. Exogenous EGF
increased tubular apoptosis and doubled atrophy in the ob-
structed kidney of waved-2 mice. Species differences in EGF
receptor localization were detected in 3-day-old kidneys.
Conclusion. EGF acts as a survival factor in the neonatal
rat, but potentiates tubular cell death in the neonatal mouse.
Species differences are maintained in cultured cells, suggest-
ing that differences in EGF receptor signaling underlie these
opposing effects.
There is increasing evidence that the initiation and pro-
gression of a variety of renal disorders involves alter-
ations in tubular apoptosis [1, 2]. Congenital obstructive
nephropathy constitutes a major cause of renal insuffi-
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ciency in infants and children [3]. To elucidate the mech-
anisms underlying the renal response to urinary tract
obstruction in the developing kidney, we have created
models of unilateral ureteral obstruction (UUO) in
neonatal rats and mice [4, 5]. In contrast to the human, in
whom nephrogenesis is complete before birth, nephro-
genesis in the rat is incomplete at birth and progresses
during the first 2 postnatal weeks. As a consequence of
UUO in the neonatal rat, there is a marked increase in
tubular apoptosis, beginning within several days of ob-
struction, and continuing for several weeks, leading to
tubular atrophy [6–8]. Factors regulating tubular apop-
tosis are therefore of significant interest, as inhibition of
apoptosis may afford a therapeutic intervention to pre-
serve functioning renal mass.
Epidermal growth factor (EGF) is a peptide that stim-
ulates proliferation, and acts as a survival factor in the
developing rat kidney [9]. EGF is normally synthesized
by distal tubular cells, with increasing expression during
maturation [4]. Chronic UUO suppresses renal EGF pro-
duction in neonatal rats or in infants and children [4, 10].
Exogenous EGF reduces tubular apoptosis by 80% in
the neonatal rat with chronic UUO, and enhances recov-
ery after relief of obstruction [11, 12]. Exogenous EGF
also inhibits tubular apoptosis in the adult rat subjected
to UUO [13]. We have reported recently that in vitro
stretching of rat tubular cells (a simulation of stretched
cells lining dilated tubules in the hydronephrotic kidney)
stimulates apoptosis. This is mediated through dephos-
phorylation of an oncoprotein, BAD, which binds to BclX
on the mitochondria, leading to release of cytochrome c
and initiation of the apoptotic cascade [14]. Incubation
of stretched tubular cells with EGF reduces apoptosis
by 50%, a response that is mediated through ERK1/2
(MAPK) signaling and maintenance of BAD phosphory-
lation [14].
Although their smaller size makes surgical models of
neonatal UUO more difficult in the mouse, the avail-
ability of mutant murine strains makes them desirable
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in studying the cellular pathophysiology of obstructive
nephropathy. Similar to the rat, nephrogenesis in the
mouse is incomplete at birth and progresses throughout
the first 2 postnatal weeks. We have recently reported
a detailed study of the cellular consequences of chronic
UUO in the neonatal mouse, showing that tubular apop-
tosis is directly proportional to tubular dilatation, and
that in vitro stretching of mouse tubular cells induces
apoptosis, as in the rat [5]. Using selectin null mutations,
we have reported that tubular apoptosis in the neona-
tal mouse subjected to UUO is also mediated in part by
infiltrating interstitial macrophages [15, 16].
To elucidate the role of EGF in tubular apoptosis fol-
lowing UUO, the present studies were performed in wild
type and mutant neonatal mice lacking functional EGF
or with a mutation of the EGF receptor, resulting in a
marked reduction in its intrinsic tyrosine kinase activity
(waved-2 mutant mice). The results were unanticipated.
In neonatal wild-type mice, exogenous EGF promotes
apoptosis instead of cell survival in the obstructed kid-
ney. In the mutant mice, either a reduction in endogenous
EGF or a reduction in EGF receptor activity promotes
cell survival, rather than apoptosis in the hydronephrotic
kidney. Different EGF/HER receptor expression pat-
terns in the developing kidneys of rats and mice may
contribute to this conundrum.
METHODS
Exogenous EGF treatment of wild-type mice subjected
to UUO
Wild-type C57BL/6J mice were subjected to complete
left ureteral obstruction or sham operation within the first
48 hours of life. Under general anesthesia with isoflurane
and oxygen, the left ureter was exposed through an in-
cision and was ligated (UUO). The incision was closed,
and the animal was returned to its mother. One day af-
ter surgery, 6 mice were injected subcutaneously with
EGF (Upstate Biotechnology, Lake Placid, NY, USA) for
7 days at a daily dose of 0.1 mg/kg body weight, and 6 mice
were injected subcutaneously with saline vehicle to serve
as controls. Mice were sacrificed 8 days after surgery, kid-
neys were removed, decapsulated, weighed, and fixed in
10% phosphate-buffered formalin (pH 7.1) for 24 to 48
hours before transfer to 70% ethanol. Kidneys were then
dehydrated, embedded in paraffin, and sectioned at 4 lm.
Mice lacking functional EGF
Mice with the EGF gene disrupted by conventional
gene targeting were obtained as heterozygote breeding
pairs [17]. To identify homozygous wild type and homozy-
gous EGF null animals for breeding, genomic DNA was
extracted from mouse tail biopsies of progeny using the
DNeasyTM Tissue Kit (Qiagen, Inc., Valencia, CA, USA),
and genotype was determined by polymerase chain re-
action using the following primers: 5′ ATA AGA TGC
TGA TGA TGC TGA TGC 3′ (forward primer, mI19-
3 in mouse intron 19), 5′ AGC TGT CCT CTA TAG
ACC TGG CTG 3′ (reverse primer, mI19-up in mouse
intron 19, wild-type allele), and 5′ CTG CAC GAG ACT
AGT GAG ACG TGC 3′ (reverse primer, PGK-2 in PGK
neo of targeted allele). Genotyped homozygous EGF null
male and female mice were bred to generate animals for
knockout study; progeny were not genotyped. Homozy-
gous wild-type littermates (a mixed background of 129
and C57BL/6J) were used as breeders for controls. New-
born male and female mice were subjected to complete
left UUO within the first 48 hours of life [18]. Seven or 14
days after operation, animals were sacrificed by pento-
barbital injection, and their kidneys were decapsulated,
removed, weighed, and processed for histologic study as
described above. N = 12 and 19 for 7-day knockout and
wild type, respectively; N = 4 and 15 for 14-day knockout
and wild type, respectively.
Waved-2 mice
The waved-2 mouse model is a spontaneous hypo-
morphic, or partial loss-of-function mutant. The waved-2
EGFR contains a single point mutation in the tyrosine
kinase domain that severely impairs its activity in vitro,
and partially impairs its activity in vivo, depending on
the tissue context and endogenous or exogenous levels
of ligands [19]. Because the waved-2 EGFR is full length
and expressed at normal levels, its signaling capacity may
be rescued via heterodimerization with other erbB/HER
receptors because it can still bind ligand, be phosphory-
lated, and recruit adaptor or effector molecules.
Homozygous mutant waved-2 mice [19] obtained from
Jackson Laboratory (Bar Harbor, ME, USA) were iden-
tified at 2 days of age by the presence of wavy vibris-
sae. Newborn male and female mice were subjected to
complete left UUO or sham operation within the first
48 hours of life [18]. Seven or 14 days after operation,
animals were sacrificed by pentobarbital injection, and
their kidneys were decapsulated, removed, weighed, and
processed for histologic study. N = 12 and 31 for 7-
day waved-2 and combined heterozygote and wild type
controls, respectively; N = 5 and 21 for 14-day waved-
2 and combined heterozygote and wild type controls,
respectively.
Administration of exogenous EGF to waved-2 mice sub-
jected to UUO. One day after surgery (below), 6 waved-
2 mice were injected subcutaneously with EGF (Up-
state Biotechnology) for 12 days at a daily dose of 0.1
mg/kg body weight. Five waved-2 animals were injected
daily with saline vehicle to serve as controls. Mice were
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sacrificed 12 days after surgery on day 14, kidneys were
removed, decapsulated, weighed, and processed for his-
tologic study. N = 11 for waved-2 and combined heterozy-
gote and wild-type controls, respectively.
Ribonucleic acid analysis by slot blot
Total RNA was extracted from frozen kidney tissue
of wild-type C57BL/6J mice, and applied to nylon mem-
branes for slot blot analysis, as previously described [4].
32P-labeled EGF and GAPDH cDNA probes, probe hy-
bridization conditions, and radiograph analysis were also
described [4].
Immunohistochemistry and histology
Kidney sections were deparaffinized in xylene, and re-
hydrated through graded ethanols. Proteinase K at 20 lg/
mL (Roche, Indianapolis, IN, USA) was applied for
15 minutes, and endogenous peroxidase activity was sup-
pressed by quenching the slides in 3% H2O2 in methanol
for 5 minutes. The following staining and immunohisto-
chemical techniques were used.
Identification of cellular apoptosis. Apoptotic cells
were identified with the TUNEL technique, using the
ApopTag peroxidase in situ Apoptosis Detection Kit
(Chemicon International, Temecula, CA, USA). Pos-
itive nuclei were visualized by applying peroxidase-
conjugated anti-digoxigenin antibody for 30 minutes,
followed by a 0.05% solution of 3,3′-diaminobenzidine
tetrahydrochloride for 4 minutes. For negative controls,
TdT enzyme was omitted. Slides were counterstained
with methylene blue. The number of apoptotic cells was
counted in each of 10 randomly selected fields.
Identification of tubular atrophy by basement mem-
brane thickening. The tubular basement membrane
(TBM) was identified by periodic acid–Schiff (PAS)
staining. Thickening and folding of the TBM has been
shown to be a reliable indicator of tubular atrophy [20].
TBM thickening was identified in 100 cross-sectioned
tubules. Results are expressed as the percentage of cross-
sectioned tubules having thickened TBM relative to
the total number of cross-sectioned tubular segments
counted.
Identification of proximal tubules with lectins. Selected
serial sections were treated for 30 minutes with biotiny-
lated Lotus tetragonobulus lectin (1:50; Vector Laborato-
ries, Burlingame, CA, USA) to identify proximal tubules
in mouse kidneys or Phaseolus vulgaris erythroagglutinin
(1:500; Vector Laboratories) to identify proximal tubules
in rat kidneys.
Identification of the EGF receptor. Rabbit anti-EGF
receptor antibody #2232 (Cell Signaling Technology, Bev-
erly, MA, USA) was diluted 1:50 in phosphate-buffered
saline (PBS) with 5% goat serum and used according
Table 1. Body weight of mice
Wild type or Homozygous
heterozygote mutant
7-day-old EGF deletion 4.75 ± 0.14 4.41 ± 0.14
7-day-old wa-2 5.04 ± 0.12 4.39 ± 0.30a
14-day-old EGF deletion 8.10 ± 0.46 6.75 ± 0.21
14-day-old wa-2 8.06 ± 0.25 7.84 ± 0.56
14-day-old wa-2 + EGF 9.01 ± 0.30 7.43 ± 0.50a
aP < 0.05 vs. wild type or heterozygote.
to the manufacturer’s recommended protocol, with no
counterstain.
In vitro mechanical stretch experiments. Proximal
tubule epithelial cells (PKSV-PR) were provided by
Dr. Alain Vandewalle (Paris, France) and were cultured
as previously described [5, 21]. Cells were grown to con-
fluence on collagen type I coated Bioflex plates (Flex-
cell International Corp., Hillsborough, NC, USA) for 7
days. Static stretch was applied to Bioflex plates with an
FX-3000 Flexercell Strain Unit (Flexcell International
Corp.), increasing the percent elongation (degree of
stretch) from zero to 20% during the first hour, then hold-
ing at 20% elongation for 4 hours. Control plates were not
subjected to stretch. At the beginning of stretch applica-
tion or the control period, recombinant EGF (20 ng/mL)
or vehicle was added to the medium. Cell monolayers
were fixed with 3.7% paraformaldehyde/PBS and perme-
abilized with ethanol/acetic acid as described previously
[5]. Cloning rings (10 mm) were used to isolate areas on
the flexible membrane for TUNEL staining with Apop-
Tag Red (Chemicon International), and staining was per-
formed according to manufacturer’s recommendations.
Coverslips were mounted with Aqua Polymount (Poly-
sciences, Inc., Warington, PA, USA). Positively stained
nuclei were counted at 200× magnification in at least
10 nonoverlapping fields from triplicate wells to deter-
mine the mean number of apoptotic nuclei per field.
Images were captured using a Leica DMIRE2 fluores-
cent microscope fitted with a Retiga Exi digital camera
(Q-Imaging, Burnaby, BC, Canada) and Simple PCI
software (Compix, Inc., Imaging Systems, Cranberry
Township, PA, USA).
Statistical analysis
Data are presented as mean ± standard error. Student
t test for unpaired variables was used to compare mu-
tants with wild type and/or heterozygotes (Tables 1 and 2,
Figs. 2 and 3), and EGF knockout groups in Figure 4.
Student t test for paired variables was used to compare
left and right kidneys in Table 2 and Figures 2 and 3.
Two-way analysis of variance (ANOVA) was performed
for waved-2 data in Figure 4B, and cell-stretch data in
Figure 7B. Statistical significance was defined as P < 0.05.
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Table 2. Kidney weight of mice
Wild type or heterozygote Homozygous mutant
UUO Intact UUO Intact
7-day-old EGF deletion 27 ± 0.9a 31 ± 1.3 29 ± 1.6 32 ± 1.4
7-day-old wa-2 27 ± 0.7a 30 ± 1.6 23 ± 2.2a 29 ± 1.7
14-day-old EGF deletion 22 ± 1.9a 69 ± 1.7 21 ± 1.1a 56 ± 6.1
14-day-old wa-2 24 ± 1.0a 67 ± 2.4 29 ± 3.4a 65 ± 5.6
14-day-old wa-2 + EGF 17 ± 1.5a 69 ± 1.6 21 ± 3.0a 59 ± 4.4b
aP < 0.05, left kidney vs. right kidney (paired t test).
bP < 0.05 vs. wild type or heterozygote (unpaired t test).
UUO
Intact
UUO
Intact
UUO
Intact
2.5 µg 5 µg
EGF
2.5 µg 5 µg
GAPDH
Fig. 1. Relative abundance of mRNA for EGF and GAPDH from ob-
structed (UUO) and intact kidneys of 14-day-old C57BL/6J wild-type
mice. Either 2.5 lg or 5.0 lg RNA was loaded in each slot. Each pair
of UUO and intact kidney RNA was obtained from a different animal
(N = 3).
RESULTS
Compared to the intact kidney, or to that of sham-
operated mice, the expression of endogenous EGF (fac-
tored for GAPDH) was reduced 78-fold after 14 days
of UUO in wild-type mice (Fig. 1). Previous studies also
showed suppression of EGF expression in the kidneys of
neonatal rats with UUO [4]. This provided a rationale
for administering exogenous EGF, which markedly at-
tenuated renal tubular injury in neonatal rats with UUO
[11]. The administration of exogenous EGF to neonatal
mice with UUO reduced the kidney weight/body weight
ratio relative to vehicle control animals (Fig. 2A). In con-
trast to rats, EGF tended to increase tubular apoptosis
(Fig. 2B) and tubular atrophy (Fig. 2C) in neonatal mice
relative to vehicle control. To further investigate this ap-
parent species difference, and to evaluate the role of en-
dogenous EGF, neonatal mutant mice that lack functional
EGF (EGF knockout), and mice with functionally defi-
cient EGF receptors (waved-2) were subjected to UUO.
As shown in Table 1, body weight for wild type or het-
erozygous mice tended to be greater than for homozygous
mutants at both 7 and 14 days of age, and the differences
were statistically significant for 7-day-old waved-2 mice,
and for 14-day-old waved-2 mice receiving exogenous
EGF. The absolute kidney weight data provided in
Table 2 indicates that suppression of renal growth re-
sulting from UUO is not significantly altered by EGF
deletion or by the waved-2 mutation. In contrast, kidney
weight/body weight ratio was 18% greater for the ob-
structed kidney of 7-day-old EGF knockout mice than
for that of the control obstructed kidney (Fig. 3A), 30%
greater than controls for the obstructed kidney of 14-
day-old EGF knockout mice (Fig. 3C), 24% greater than
controls for the obstructed kidney of 14-day-old waved-2
mice (Fig. 3D), and 53% greater than controls for 14-day-
old waved-2 mice receiving EGF (Fig. 3E). There was also
an increase in kidney weight/body weight ratio for the in-
tact kidney of EGF knockout compared to control mice
(Figs. 3A and C). Regardless of genotype, growth of the
obstructed kidney at 14 days was significantly impaired
in the obstructed compared to the contralateral kidney
(Figs. 3C, D, and E).
Compared to wild-type animals, renal tubular apopto-
sis in 14-day-old mice with UUO was reduced by 50%
in EGF knockout animals (Fig. 4A). A similar reduction
in apoptosis was found in waved-2 homozygous mutant
mice compared to combined wild type and heterozygous
animals. However, the administration of exogenous EGF
to waved-2 homozygous mice prevented the reduction in
apoptosis, which was not different from the response of
combined wild type and heterozygous mice (Fig. 4A).
There was a trend to reduced tubular atrophy in the ob-
structed kidney of 14-day-old EGF knockout and waved-
2 homozygotes compared to heterozygotes or wild-type
mice, but differences were not significant (Fig. 4B). The
administration of exogenous EGF doubled tubular at-
rophy in the obstructed kidney regardless of genotype
(P < 0.05) (Fig. 4B).
Combined results from the wild type and mutant mouse
studies indicate that detrimental effects of EGF are me-
diated by EGF binding to its receptor, even a receptor
with diminished tyrosine kinase activity. This led us to
question whether there might be species differences in
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Fig. 2. Effects of exogenous EGF administered to wild-type C57BL/6J
neonatal mice. (A) Kidney weight/body weight ratio (mg/g) for left
obstructed (UUO) and right (intact) kidneys harvested from 10-day-
old mice. Solid bars represent vehicle-treated animals and hatched bars
represent EGF-treated animals. ∗P < 0.05, intact vs. UUO, #P < 0.05,
vehicle vs. EGF-treated (UUO). (B) Number of apoptotic cells per field,
measured by TUNEL assay in 10-day-old vehicle- or EGF-treated mice.
Solid bars, left obstructed (UUO) kidneys; hatched bars, right (intact)
kidneys. ∗P < 0.05, UUO vs. intact. (C) Number of atrophic tubules per
field, identified by thickened tubular basement membranes on PAS-
stained sections of 10-day-old mice. Groups and legends as for (B).
∗P < 0.05, UUO vs. intact.
EGF receptor expression or localization in the devel-
oping kidney. In sham-operated kidneys of 14-day-old
wild-type C57BL/6J mice, the EGF receptor was abun-
dantly expressed in the basal membrane folds of proxi-
mal tubules, as shown in serial sections (Fig. 5A and B).
In contrast, the EGF receptor was detected in apical and
lateral membranes of dilated tubules in 14-day-old ob-
structed mouse kidneys (Fig. 5C). The pattern of the EGF
receptor expression was similar in 14-day-old rat kidneys:
basal membranes of proximal tubules in sham-operated
kidneys (Fig. 5D and E) and apical membranes of dilated
tubules in UUO kidneys. Although no species differences
were detected in 14-day-old kidneys, striking differences
were apparent in 3-day-old sham kidneys. In 3-day-old
vehicle control mouse kidneys, the EGF receptor was de-
tected in membranes of glomerular cells and the apical
membranes of some tubules (Fig. 6A). Twenty-four hours
after exogenous EGF administration, expression of the
EGF receptor in 3-day-old mouse kidneys increased, and
was detected in the basal folds of proximal tubules
(Fig. 6B). In contrast, abundant EGF receptor expression
was already localized in the basal membranes of 3-day-
old rat proximal tubules, and exogenous EGF treatment
caused no apparent change in expression level or local-
ization (Fig. 6C and D). This suggests that developmental
timing of EGF receptor expression may be different in the
2 rodent species.
To determine if EGF-induced apoptosis is an intrin-
sic response of mouse tubular cells, we used an in vitro
culture model. Axial strain applied to cultured mouse
tubular cells increased apoptosis by more than 2-fold
(Fig. 7A and B). The addition of exogenous EGF further
increased apoptosis in both control and stretched cells
(P < 0.05), and this increase was independent of mechan-
ical stretch–induced apoptosis (Fig. 7B).
DISCUSSION
The present study demonstrates that tubular apopto-
sis was reduced in the obstructed kidneys of EGF null
mutants or waved-2 mutant mice (EGF-receptor kinase
mutants) relative to obstructed kidneys of wild type
or heterozygote controls. Administration of exogenous
EGF increased renal apoptosis in waved-2 mice, and
increased tubular atrophy in wild type, heterozygous,
or mutant waved-2 mice. The latter is consistent with
tubular apoptosis, contributing to progressive tubular
atrophy [22]. Moreover, enhancement of apoptosis by ex-
ogenous EGF in cultured mouse tubular cells subjected to
axial strain contrasts with the suppression of apoptosis by
EGF in stretched rat tubular cells [14]. This indicates that
the contrasting species-specific renal tubular responses to
EGF are maintained in immortalized cultured cells.
We have shown in both neonatal rats and mice sub-
jected to complete UUO that the obstructed kidney fails
to grow [4, 5]. We have also recently reported that severe
partial UUO impairs renal growth in proportion to the
severity of obstruction [23]. While lack of endogenous
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Fig. 3. Kidney weight/body weight ratio (mg/g) for left obstructed (UUO) and right (intact) kidneys of neonatal mice. Solid bars represent wild
type or combined wild type and heterozygous mice; hatched bars represent homozygous mutant mice. (A) Seven-day-old EGF knockout mice;
(B) 7-day-old waved-2 mice; (C) 14-day-old EGF knockout mice; (D) 14-day-old waved-2 mice; (E) 14-day-old waved-2 mice receiving exogenous
EGF. ∗P < 0.05 vs. wild-type or heterozygous mice, ∗∗P < 0.05 vs. contralateral kidney (UUO).
EGF increases the relative growth of the obstructed or
contralateral kidney (Figs. 3A and C), exogenous EGF
impairs the growth of the obstructed mouse kidney
(Fig. 2A). Somatic growth tended to be reduced in the
murine mutants compared to wild type or heterozygous
controls (Table 1). While the administration of exogenous
EGF to adult rats increases kidney growth [24], EGF
impairs renal and hepatic growth of neonatal rats, but
does not affect growth of heart or liver [25]. Treatment
of normal neonatal mice with EGF inhibits renal cellu-
lar proliferation [26], a finding that is consistent with the
present study. Taken together, these results suggest that
the effects of EGF on growth are organ-specific, and de-
velopmentally determined.
Both EGF mRNA and immunoreactive EGF are de-
tectable in the distal nephron of the mouse by 3 to 5 days
postnatally [27]. By the second postnatal week, EGF is
expressed by medullary as well as cortical regions, and is
localized to the thick ascending limb of Henle and distal
convoluted tubule [27]. In the mouse, renal EGF content
increases 20-fold from 1 to 3 weeks of life, and peaks at
5 to 7 weeks [28]. As shown in the present study, chronic
UUO markedly suppresses the developmental increase
in renal EGF expression. In the rat, EGF is expressed
in proximal tubules by gestational day 19, and in distal
tubules by postnatal day 7 [29]. As in the mouse, there is
a progressive increase in renal EGF expression through-
out the first month of life in the rat, which is suppressed
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Fig. 4. Effect of mutations on markers of tubular cell injury. (A) Num-
ber of apoptotic cells per field, measured by the TUNEL assay in the
obstructed kidney of 14-day-old mice. EGF ko, EGF knockout; wa-2,
waved-2; wa-2 + EGF, waved-2 mice receiving exogenous EGF. Solid
bars represent wild type or combined wild type and heterozygous mice;
hatched bars represent homozygous mutant mice, ∗P < 0.05 vs. wild-
type or heterozygous mice. (B) Number of atrophic tubules per field,
identified by thickened tubular basement membranes on PAS-stained
sections in the obstructed kidney of 14-day-old mice. Groups and leg-
ends as in Figure 3. Exogenous EGF administration increased tubular
atrophy in both waved-2 and wild type combined with heterozygous
control mice (P < 0.05).
by chronic UUO in the neonatal period [4]. There is an
increase in EGF receptor abundance and activation in
late gestation in the rat, falling toward adult levels during
the first postnatal week [30]. In man, EGF is localized
in S-shaped mesonephric vesicles of 6-week embryos, as
well as in the blastemic caps of the metanephros [31].
EGF receptor is localized to the ureteric bud branches
of the metanephros of the 6-week embryo, and to the
collecting ducts by 11 weeks and later [31]. There are rel-
atively minor differences between the DNA sequences
of preproEGF in mouse, rat, and man, suggesting that
species-specific differences in the response to EGF are
due to variations in receptor signaling [32].
Despite the similarities across mammalian species in
the renal development of EGF and its receptors, the
dramatic contrasts in the cellular responses to EGF be-
tween rats and mice clearly have important implications
if growth factors are to be used as therapeutic agents
in renal disease. In the developing rat kidney, normal
mesenchymal cell apoptosis in the nephrogenic zone and
medullary papilla can be inhibited by exogenous EGF ad-
ministration [9]. In this circumstance, interference with
apoptosis that is part of normal developmental remod-
eling may prove injurious, as postulated for the renal
anomalies of rats lacking the AT2 angiotensin receptor
[33]. Using an in vitro model of rat metanephric develop-
ment, exogenous EGF was shown to rescue mesenchyme
from apoptosis, but did not lead to differentiation [34].
In a model of ischemic renal failure in the rat, exogenous
EGF was shown to enhance renal tubular regeneration
and repair by increasing tubular proliferation (apoptosis
was not measured) [35]. In contrast, renal injury following
renal ablation or renal ischemia in the mouse is attenu-
ated in animals expressing a dominant-negative EGF re-
ceptor in the kidney (apoptosis was not measured in this
study) [36]. Exposure of cultured mouse kidney cells to
EGF induces de novo expression of Fsp1, a gene encod-
ing a fibroblast-specific protein associated with epithelial-
mesenchymal transformation in vivo [37]. This process,
in turn, is likely to play a major role in the evolution of
glomerular and interstitial fibrosis, which figures promi-
nently in all chronic progressive renal disease. In a prelim-
inary study, waved-2 mice were found to have markedly
less nephrosclerosis and albuminuria than wild-type lit-
termates receiving angiotensin II infusion and high-salt
diet [abstract; Ciroldi M et al, J Am Soc Nephrol 14:617A,
2003). This effect was postulated to be mediated by trans-
forming growth factor-a, an alternate ligand for the EGF
receptor.
Heparin binding EGF (HB-EGF) is another ligand for
the EGF receptor. Following complete UUO in the adult
mouse, there is a transient rise in renal HB-EGF pro-
duction, peaking 6 hours after UUO, and returning to
baseline 24 hours after UUO [38]. Mouse tubular cells
subjected to axial strain also increase HB-EGF produc-
tion, while tubular cells transfected with HB-EGF were
protected from stretch-induced apoptosis [38]. These re-
sults demonstrate that other EGF receptor ligands may,
in fact, play a protective role in attenuating the tubular
injury resulting from UUO in the mouse.
There has been significant interest in manipulating the
EGF receptor as a means of reducing renal injury and dys-
function in animal models of polycystic kidney disease.
There are a number of parallels between the renal lesion
of obstructive nephropathy and cystic kidney diseases,
including focal cystic dilatation of the tubule in the for-
mer, and tubular obstruction in the latter [39]. Moreover,
in both obstructive nephropathy and cystic kidney dis-
ease, renal tubular expression of EGF is suppressed, the
renin-angiotensin system is activated, and dilated tubules
Kiley et al: EGF potentiates cell death in neonatal mice, but survival in rats 511
Fig. 5. Representative photomicrographs of
14-day-old neonatal mouse and rat kidneys.
Left column: serial sections of sham-operated
wild-type C57BL/6J mouse kidney stained
with (A) Lotus tetragonobulus lectin, a marker
for proximal tubule brush border in mouse,
and (B) anti-EGF receptor (EGFR) antibody.
(C) Obstructed (UUO) wild type mouse kid-
ney stained with anti-EGFR antibody. Right
column: serial sections of sham Sprague-
Dawley rat kidney stained with (D) Phaseo-
lus vulgaris erythroagglutinin lectin, a marker
for proximal tubule brush border in rat, and
(E) anti-EGFR antibody. (F) Obstructed rat
kidney stained with anti-EGFR antibody. Bar
inset, 50lm.
Fig. 6. Representative photomicrographs of
EGF receptor localization in 3-day-old neona-
tal mouse and rat kidneys. Sham kidneys from
neonatal wild-type C57BL/6J mice injected
with saline vehicle (A) or EGF (B) 24 hours
before harvest on day 3. Sham kidneys from
neonatal rats injected with vehicle (C) or EGF
(D) 24 hours prior to harvest. Bar inset, 50lm.
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Fig. 7. Effect of EGF on control mouse
PKSV-PR cell cultures versus cultures under-
going mechanical stretch. (A) Representative
images of TUNEL staining for each experi-
mental condition; control versus stretch and
vehicle- versus EGF-treated cultures at 200×
magnification. (B) Number of apoptotic nu-
clei per field for confluent mouse tubular ep-
ithelial cell monolayers subjected to 20% dis-
tention by continuous axial strain (right), or
control nonstretched conditions (left). Solid
bar, control cells; hatched bar, cells treated
with exogenous EGF; ∗P < 0.05 EGF-treated
vs. control cells. Stretch increased apopto-
sis independent of EGF administration (P <
0.05).
undergo apoptosis [39]. Using a genetic approach, waved-
2 mice were crossed with Oak Ridge polycystic kidney
(orpk) mice with autosomal-recessive polycystic kidney
disease [40]. The mice with cystic kidney disease carry-
ing the waved-2 mutation had significant attenuation of
collecting duct cysts and improved kidney function com-
pared to homozygous orpk mice [40]. Interestingly, as
demonstrated in the present study with chronic UUO,
EGFR is localized to the apical surface of tubular cells
in mice with cystic kidney disease [40]. Treatment of 2-
to 3-week-old Balb/c polycystic kidney (bpk/bpk) mice
with an EGF receptor tyrosine kinase inhibitor amelio-
rates this form of polycystic kidney disease [41]. These
responses are consistent with our studies of UUO in
waved-2 mice. However, treatment of 3- to 9-day-old bpk
mice with EGF retards the development of azotemia,
while extension of treatment beyond 9 days increases
morbidity [42]. These reports suggest that, in addition to
species differences, the maturational stage of the animal
affects the tubular response to EGF.
In the present study, the administration of exoge-
nous EGF to waved-2 mice increased apoptosis in the
obstructed kidney similar to levels measured in wild
type or heterozygous controls (Fig. 4A). EGF also in-
creased tubular atrophy (Fig. 4B). Assuming that the
waved-2 mutation markedly reduced the intrinsic tyro-
sine kinase activity of the EGF receptor, it is likely
that coexpressed alternate receptors pair with the mu-
tant receptor to rescue EGFR signaling. The epidermal
growth factor receptor family consists of the EGF recep-
tor (EGFR/HER1) and 3 alternate receptors, HER2/neu,
HER3, and HER4 [43, 44]. HER2 has no ligand and is
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the preferred heterodimerization partner for the other 3
family members. EGF binds primarily to EGFR, but at
high concentrations can also bind with low affinity to the
HER2/HER3 heterodimer [45, 46]. Heregulin binds to
both HER3 and HER4. The EGF-induced high-affinity
EGFR/HER2 heterodimer is relatively short-lived and
EGFR is downmodulated upon dissociation from HER2
[43]. EGF-“activated” HER2 is then potentially free to
couple with HER3 or HER4 to transmit EGF signaling
laterally through these alternate receptors [43]. A recent
study indicates that heregulin and its receptors are coex-
pressed in the developing mouse kidney: HER3 is abun-
dant in ureteric bud epithelia of the fetal mouse kidney
and disappears from proximal tubules between days 5 and
15 after birth [abstract; Polgar K et al, J Am Soc Nephrol
14:357A, 2003]. In neonatal rats, HER3 is detected only
in the renal vasculature (M.S.F. and S.C.K., unpublished
observation). Because EGF was administered on day 3
after birth and for 7 days afterward in our mouse stud-
ies, it is likely that HER3 was expressed on the proximal
tubules during the EGF treatment period, and may have
been activated by lateral signaling of HER2 or by direct
binding of EGF to EGFR/HER3 or HER2/HER3 het-
erodimers [abstract; Kiley SC et al, Mol Biol Cell 15S:13a,
2004]. A constitutive src kinase activity in mouse, but not
rat, kidney may activate HER2 in the absence of waved-
2 EGFR kinase activity [abstract; Kiley SC et al, J Am
Soc Nephrol 14:324A, 2003]. Once dissociated from the
mutant EGFR, “activated” HER2 could potentially acti-
vate the heregulin/HER3 apoptosis pathway in neonatal
mouse kidneys [44, 47].
CONCLUSION
In man, inhibition of EGF has been used to suppress
tumor proliferation, or to induce apoptosis of malignant
cells [48, 49]. On the other hand, exogenous EGF may be
clinically therapeutic in promoting the repair of tissues
damaged by bowel inflammation [50]. Based on studies
in rats and mice, EGF-receptor tyrosine kinase inhibitors
have been proposed as potential therapy for human poly-
cystic kidney disease [41, 51]. The dramatic differences
in the renal cellular response to EGF administered to
neonatal mice compared to rats with chronic UUO high-
light the importance of thoroughly understanding EGF-
receptor signaling before embarking on clinical trials.
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